尿路里图西马布的损失和治疗失败率在膜性脏病的治疗失败率
Marco Allinovi1, Matteo Accinno2, Cecilia Finocchi1
1Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy.
在原发性膜性病中,尿路里图西马布的流失与疾病的严重程度和治疗失败有关. 测量尿路里图西马布可以识别需要额外剂量的患者,以获得更好的结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 利图西马布是对一次性膜性病 (PMN) 的一线治疗方法.
- 大约三分之一的PMN患者表现出对rituximab的耐药性.
- 由于蛋白尿症而导致的尿路里图西马布损失是抗药性的假设原因.
研究的目的:
- 客观地测量PMN患者的尿路里图西马布损失.
- 为了研究尿路里图西马布水平,疾病严重程度和治疗反应之间的关联.
- 为了探索额外的Rituximab剂量的潜在益处在非响应者与尿失.
主要方法:
- 对25名PMN患者进行前性观察性研究,这些患者接受了Rituximab治疗.
- 使用ELISA测量血清和尿液里图西马布水平.
- 确定了尿路里图西马布存在的门值;高尿路里图西马布不响应者接受了第二次治疗.
主要成果:
- 尿路里图西马布的损失与较低的EGFR,较高的蛋白尿和非选择性蛋白尿相关.
- 尿中Rituximab含量高 (≥2μg/mL) 的患者的血清水平较低,反应率较差 (43%与100%相比),以及PLA2R抗体减少的频率较低.
- 在8名重新治疗的非响应患者中,有5名在尿路中失去利图西马布,实现了临床响应.
结论:
- 尿路里图西马布的流失与PMN严重程度,图西马布暴露不足和治疗失败有关.
- 尿路Rituximab测量可以识别患有耐药性风险的患者.
- 这种方法可以指导个性化的Rituximab剂量策略,以改善患者的治疗结果.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
06:46Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure
Published on: December 22, 2023
相关概念视频
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Continuous Renal Replacement Therapy
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Kidney Transplant II: Surgical Procedure
Nephrotic Syndrome II : Assessment and Medical Management
Urinary Tract Infection IV: Nursing Management
